Key result
Nadroparin fails to reduce poor outcomes vs placebo in cerebral sinus thrombosis.
RCT (n=60)
Double-blind (first 3 weeks), Open-label (subsequent 3 months)
Randomized
Yes
Answers are grounded in this paper and cite their sources.
BACKGROUND AND PURPOSE: Treatment of cerebral sinus thrombosis with heparin is controversial. We conducted a double-blind, placebo-controlled multicenter trial to examine whether anticoagulant treatment improves outcome in patients with sinus thrombosis. METHODS: Patients were randomized between body weight-adjusted subcutaneous nadroparin (180 anti-factor Xa units/kg per 24 hours) and matching placebo for 3 weeks (double-blind part of trial), followed by 3 months of oral anticoagulants for patients allocated nadroparin (open part). Patients with cerebral hemorrhage caused by sinus thrombosis were also included. RESULTS: Sixty patients were enrolled, and none were lost to follow-up. In 1 patient the diagnosis proved wrong after randomization. After 3 weeks, 6 of 30 patients (20%) in the nadroparin group and 7 of 29 patients (24%) in the placebo group had a poor outcome, defined as death or Barthel Index score of <15 (risk difference, -4%; 95% CI, -25 to 17%; NS). After 12 weeks, 4 of 30 patients (13%) in the nadroparin group and 6 of 29 (21%) in the placebo group had a poor outcome, defined as death or Oxford Handicap Score of >/=3 (risk difference, -7%; 95% CI, -26% to 12%; NS). There were no new symptomatic cerebral hemorrhages. One patient in the nadroparin group had a major gastrointestinal hemorrhage, and 1 patient in the placebo group died from clinically suspected pulmonary embolism. CONCLUSIONS: Patients with cerebral sinus thrombosis treated with anticoagulants (low-molecular-weight heparin followed by oral anticoagulation) had a favorable outcome more often than controls, but the difference was not statistically significant. Anticoagulation proved to be safe, even in patients with cerebral hemorrhage.
No takes yet. Share an insight, caveat, or question.
Bruijn et al. (1999) conducted an RCT in Cerebral sinus thrombosis (n=60). Subcutaneous nadroparin followed by oral anticoagulants vs. Matching placebo was evaluated on Poor outcome at 12 weeks, defined as death or Oxford Handicap Score of >=3 (also assessed at 3 weeks as death or Barthel Index score <15) (Risk difference -7%, 95% CI -26% to 12%, p=NS). Nadroparin followed by oral anticoagulation did not reduce poor outcomes at 12 weeks vs placebo in cerebral sinus thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: